Compare BCS & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCS | REGN |
|---|---|---|
| Founded | 1690 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.4B | 59.5B |
| IPO Year | N/A | 1991 |
| Metric | BCS | REGN |
|---|---|---|
| Price | $23.41 | $722.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 23 |
| Target Price | N/A | ★ $793.74 |
| AVG Volume (30 Days) | ★ 5.6M | 1.1M |
| Earning Date | 10-22-2025 | 10-28-2025 |
| Dividend Yield | ★ 1.86% | 0.49% |
| EPS Growth | ★ 45.84 | 2.88 |
| EPS | 0.54 | ★ 41.59 |
| Revenue | ★ $34,970,562,135.00 | $14,247,800,000.00 |
| Revenue This Year | $20.45 | $1.95 |
| Revenue Next Year | $5.12 | $5.47 |
| P/E Ratio | ★ $10.13 | $17.38 |
| Revenue Growth | ★ 10.24 | 2.89 |
| 52 Week Low | $12.14 | $476.49 |
| 52 Week High | $23.57 | $800.99 |
| Indicator | BCS | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.41 | 56.05 |
| Support Level | $22.95 | $720.07 |
| Resistance Level | $22.91 | $790.98 |
| Average True Range (ATR) | 0.33 | 21.86 |
| MACD | 0.18 | -5.25 |
| Stochastic Oscillator | 94.32 | 34.89 |
Barclays is a universal bank headquartered in the United Kingdom. It operates via five principal segments; UK (retail), UK corporate bank, private bank and wealth management, investment bank, and US consumer bank. In its UK segment, the bank provides current accounts, mortgages, savings and investment management services, credit cards, and business banking services to retail clients and small and medium-size enterprises. The international segment includes a corporate bank offering banking solutions to large corporates, a bulge-bracket global investment bank, and a credit card and payments business.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).